Chicago Bears quarterback Caleb Williams has made it clear he had lofty goals for his NFL career. And despite a rocky rookie ...

Ever feel like you’re not doing enough? We’ve all been there, questioning the worth of our accomplishments, especially in an era where everything demands a curated “Pinterest aesthetic”. Burnout has ...

Doing school or office work at home can be challenging, especially if you don’t have a space designed for focus and purpose. Without a clear separation between personal life and productivity, it’s ...

(RTTNews) - Viatris Inc. (VTRS), Thursday announced positive top-line results from VEGA-3, evaluating MR-141 in patients with presbyopia, the progressive loss of the ability to focus on close objects.

The study results confirm controlled and real-world clinical evidence of PoNS Therapy’s long-term benefits already reported in people with balance deficit due to traumatic brain injury (TBI).

A boy from Tallahassee is making international headlines by earning a spot in the Guinness World Records. At just 3 years old, Caleb Stewart became the world’s youngest motivational speaker ...

An education programme that encourages hands-on learning has served more than 7,800 young people since it was formed ten years ago. Endeavour, a registered charity, has released its 2024 impact ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the Essence study of olezarsen in people with moderate hypertriglyceridemia (fasting triglycerides ≥150 ...

Compass Therapeutics' Phase 2/3 trial shows tovecimig plus paclitaxel significantly improves response rates in advanced biliary tract cancer patients.

Struggling to find motivation for work or study is a universal experience, but for many people there is little thought given to the reason behind a dip in enthusiasm.

INmune Bio announces positive results for CORDStrom in treating pediatric RDEB, plans for regulatory submissions, and upcoming studies.

Merck & Co. has ended another late-stage study of its Winrevair treatment for pulmonary arterial hypertension, or PAH, early due to strong evidence of the drug's benefit. Merck on Thursday said ...